Why is Aldeyra Therapeutics facing a securities class action lawsuit?

Investors allege Aldeyra made misleading statements about the reliability of clinical trial results for its drug candidate reproxalap.

What are investors claiming about Aldeyra’s clinical trial results?

The complaint alleges the trial results were inconsistent, making any reported positive findings unreliable.

What is reproxalap and why is it important to Aldeyra?

Reproxalap is a key drug candidate under development, and its success is critical to Aldeyra’s future growth and valuation.

Why are inconsistent clinical trial results a concern for investors?

Inconsistent results can undermine confidence in a drug’s effectiveness and reduce the likelihood of regulatory approval.

What are investors alleging Aldeyra failed to disclose?

Plaintiffs claim the company did not fully disclose the extent of inconsistencies in its clinical trial data.

How can unreliable trial data affect Aldeyra’s stock price?

If trial results are less reliable than expected, investors may reassess approval prospects, leading to stock declines.

What does it mean that findings were “not meaningful”?

It suggests the data may not provide strong or consistent evidence of the drug’s effectiveness.

Why are clinical trial disclosures important in biotech companies?

Biotech valuations depend heavily on trial outcomes, so accurate and transparent reporting is critical for investors.

Who may qualify to participate in the Aldeyra class action?

Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the Aldeyra lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by May 29, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which alleged misleading statements occurred and investors may have purchased shares.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all class members.

Do investors need to pay legal fees to join a securities class action?

Most securities class actions are handled on a contingency basis, meaning attorneys are paid only if there is a recovery.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting their trades to receive a portion of the settlement fund.

Aldeyra Therapeutics, Inc. - Faruqi & Faruqi LLP

Aldeyra Therapeutics, Inc.

Join Action

Case Details

Ticker ALDX

Class Period 11/03/2023 - 03/16/2026

Lead Plaintiff Deadline 05/29/2026

Days Left to Seek Plaintiff

If you are a Aldeyra Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) The results of the reproxalap (an Aldeyra drug candidate) clinical trials were inconsistent; (2) the inconsistency of the results rendered any purported positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants’ statements about Aldeyra’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damage.

Lead Plaintiff Deadline: May 29, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Aldeyra Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify